Nadine Denise van Kleef

Ms. Nadine Denise van Kleef

UMC Utrecht
+1
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2022 in Cells
Verified
Journal Article
Open access
PDF file
ESEvelien G.G. Sprenkeler
Evelien G.G. Sprenkeler
JZJudith Zandstra
Judith Zandstra
NKNadine Denise van Kleef
Nadine Denise van Kleef
IGInes Goetschalckx
Ines Goetschalckx
BVBibian Verstegen
Bibian Verstegen
TKTaco W. Kuijpers
Taco W. Kuijpers
Neutrophils are the most abundant innate immune cells in the circulation and they are the first cells recruited to sites of infection or inflammation. Almost half of the intracellular protein content in neutrophils consists of S100A8 and S100A9, though there has been controversy about their actual localization. Once released extracellularly, these proteins are thought to act as damage-associated molecular patterns (DAMPs), though their mechanism of action is not well understood. These S100 proteins mainly form heterodimers (S100A8/A9, also known as calprotectin) and this heterocomplex is recognized as a useful biomarker for several inflammatory diseases. We observed that S100A8/A9 is highly present in the cytoplasmic fraction of neutrophils and is not part of the granule content. Furthermore, we found that S100A8/A9 was not released in parallel with granular content but upon the formation of neutrophil extracellular traps (NETs). Accordingly, neutrophils of patients with chronic granulomatous disease, who are deficient in phorbol 12-myristate 13-acetate (PMA)-induced NETosis, did not release S100A8/A9 upon PMA stimulation. Moreover, we purified S100A8/A9 from the cytoplasmic fraction of neutrophils and found that S100A8/A9 could induce neutrophil activation, including adhesion and CD11b upregulation, indicating that this DAMP might amplify neutrophil activation.

18 July 2022 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
MCMichelle A. Cruz
Michelle A. Cruz
DBDillon Bohinc
Dillon Bohinc
EAElizabeth A. Andraska
Elizabeth A. Andraska
JAJurgis Alvikas
Jurgis Alvikas
SRShruti Raghunathan
Shruti Raghunathan
ESEvi X. Stavrou
Evi X. Stavrou

27 January 2022 in Blood
Verified
Journal Article
Closed access
PDF file
SMSteven de Maat
Steven de Maat
CCChantal C. Clark
Chantal C. Clark
ABArjan Barendrecht
Arjan Barendrecht
SSSimone Smits
Simone Smits
NKNadine Denise van Kleef
Nadine Denise van Kleef
CMCoen Maas
Coen Maas
Thrombotic microangiopathies are hallmarked by attacks of disseminated microvascular thrombosis. In thrombotic thrombocytopenic purpura (TTP), this is caused by a rise in thrombogenic ultra-large von Willebrand factor (VWF) multimers because of ADAMTS13 deficiency. We previously reported that systemic plasminogen activation is therapeutic in a TTP mouse model. In contrast to its natural activators (ie, tissue plasminogen activator and urokinase plasminogen activator [uPA]), plasminogen can directly bind to VWF. For optimal efficacy and safety, we aimed to focus and accelerate plasminogen activation at sites of microvascular occlusion. We here describe the development and characterization of Microlyse, a fusion protein consisting of a high-affinity VHH targeting the CT/CK domain of VWF and the protease domain of uPA, for localized plasminogen activation on microthrombi. Microlyse triggers targeted destruction of platelet-VWF complexes by plasmin on activated endothelial cells and in agglutination studies. At equal molar concentrations, Microlyse degrades microthrombi sevenfold more rapidly than blockade of platelet-VWF interactions with a bivalent humanized VHH (caplacizumab*). Finally, Microlyse attenuates thrombocytopenia and tissue damage (reflected by increased plasma lactate dehydrogenase activity, as well as PAI-1 and fibrinogen levels) more efficiently than caplacizumab* in an ADAMTS13−/− mouse model of TTP, without affecting hemostasis in a tail-clip bleeding model. These findings show that targeted thrombolysis of VWF by Microlyse is an effective strategy for the treatment of TTP and might hold value for other forms of VWF-driven thrombotic disease.

5 November 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
WSWariya Sanrattana
Wariya Sanrattana
TSThibaud Sefiane
Thibaud Sefiane
SSSimone Smits
Simone Smits
NKNadine Denise van Kleef
Nadine Denise van Kleef
MFMarcel H. Fens
Marcel H. Fens
SMSteven de Maat
Steven de Maat
Significance: Serine protease inhibitors (SERPINs) regulate vital physiological processes. Considerable research effort has gone into the development of SERPINs as therapeutic agents. One of the development goals is SERPIN modification for improved specificity toward desired target(s). The specificity and potency of SERPINs can be altered by changing their reactive center loop (RCL). Currently, predicting these properties of a RCL sequence is almost impossible. By characterizing 160 α1-antitrypsin RCL variants with single–amino acid substitutions, we developed a SERPIN RCL-based platform that predicts the inhibitory behavior for SERPIN variants with compounded RCL mutations. This platform was applied to design a next-generation SERPIN against activated protein C and provides evidence for its value in the treatment of hemophilia A.

21 December 2022 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
JVJudith de Vries
Judith de Vries
CVChantal Visser
Chantal Visser
LGLotte Geers
Lotte Geers
JSJohan A. Slotman
Johan A. Slotman
NKNadine Denise van Kleef
Nadine Denise van Kleef
MMMoniek P.M. Maat
Moniek P.M. Maat
Severe acute respiratory syndrome coronavirus 2 infection is associated with an increased incidence of thrombosis. By studying the fibrin network structure of coronavirus disease 2019 (COVID‐19) patients, we aimed to unravel pathophysiological mechanisms that contribute to this increased risk of thrombosis. This may contribute to optimal prevention and treatment of COVID‐19 related thrombosis. In this case‐control study, we collected plasma samples from intensive care unit (ICU) patients with COVID‐19, with and without confirmed thrombosis, between April and December 2020. Additionally, we collected plasma from COVID‐19 patients admitted to general wards without thrombosis, from ICU patients with pneumococcal infection, and from healthy controls. Fibrin fiber diameters and fibrin network density were quantified in plasma clots imaged with stimulated emission depletion microscopy and confocal microscopy. Finally, we determined the sensitivity to fibrinolysis. COVID‐19 ICU patients (n = 37) and ICU patients with pneumococcal disease (n = 7) showed significantly higher fibrin densities and longer plasma clot lysis times than healthy controls (n = 7). No differences were observed between COVID‐19 ICU patients with and without thrombosis, or ICU patients with pneumococcal infection. At a second time point, after diagnosis of thrombosis or at a similar time point in patients without thrombosis, we observed thicker fibers and longer lysis times in COVID‐19 ICU patients with thrombosis (n = 19) than in COVID‐19 ICU patients without thrombosis (n = 18). Our results suggest that severe COVID‐19 is associated with a changed fibrin network structure and decreased susceptibility to fibrinolysis. Because these changes were not exclusive to COVID‐19 patients, they may not explain the increased thrombosis risk.

15 October 2021 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
WSWariya Sanrattana
Wariya Sanrattana
SSSimone Smits
Simone Smits
ABArjan Barendrecht
Arjan Barendrecht
NKNadine Denise van Kleef
Nadine Denise van Kleef
HOHinde El Otmani
Hinde El Otmani
CMCoen Maas
Coen Maas
Background Occlusive thrombi are not homogeneous in composition. The core of a thrombus is rich in activated platelets and fibrin while the outer shell contains resting platelets. This core is inaccessible to plasma proteins. We produced a fusion protein (targeted SERPIN – TaSER), consisting of a function-blocking VHH against glycoprotein Ibα and a thrombin-inhibiting serine protease inhibitor (SERPIN; α1-antitrypsin 355AIAR358) to interfere with platelet-driven thrombin formation. Aim To evaluate the antithrombotic properties of TaSER. Methods Besides TaSER, we generated three analogous control variants with either a wild-type antitrypsin subunit, a non-targeting control VHH, or their combination. We investigated TaSER and controls in protease activity assays, (platelet-dependent) thrombin generation assays and by western blotting. The effects of TaSER on platelet activation and von Willebrand Factor (VWF)-binding were studied by FACS, in agglutination studies and in ATP secretion experiments. We studied the influence of TaSER in whole blood 1) on platelet adhesion on VWF, 2) aggregate formation on collagen and 3) thrombus formation (after recalcification) on collagen and tissue-factor. Results TaSER binds platelets and inhibits thrombin activity on the platelet surface. It blocks VWF binding and disassembles platelet agglutinates. TaSER delays tissue factor-triggered thrombin generation and ATP secretion in platelet-rich plasma in a targeted manner. In flow studies, TaSER interferes with platelet adhesion and aggregate formation due to GPIbα blockade and limits thrombus formation due to targeted inhibition of platelet-dependent thrombin activity. Conclusion The synergy between the individual properties of TaSER makes it a highly effective antithrombotic agent with possible clinical implications.